Rafael (NYSE:RFL) Stock Price Up 4.2% – Still a Buy?

Shares of Rafael Holdings, Inc. (NYSE:RFL) traded up 4.2% on Thursday . The stock traded as high as $2.59 and last traded at $2.3870. Approximately 182,359 shares were traded during mid-day trading, an increase of 53% from the average daily volume of 119,023 shares. The stock had previously closed at $2.29.

Analyst Ratings Changes

Several brokerages have issued reports on RFL. Wall Street Zen upgraded shares of Rafael to a “hold” rating in a report on Saturday, July 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Rafael in a report on Tuesday, August 25th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Rafael Price Performance

The business has a 50-day moving average of $2.23 and a two-hundred day moving average of $1.81. The company has a market cap of $124.12 million, a P/E ratio of -3.51 and a beta of 0.40.

Institutional Trading of Rafael

Institutional investors have recently modified their holdings of the company. Marshall Wace LLP bought a new position in shares of Rafael during the 2nd quarter worth approximately $50,000. Citadel Advisors LLC grew its holdings in Rafael by 132.3% in the third quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock worth $99,000 after purchasing an additional 41,335 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Rafael by 59.1% in the first quarter. Renaissance Technologies LLC now owns 89,138 shares of the company’s stock worth $111,000 after purchasing an additional 33,111 shares during the last quarter. Cable Car Capital LP acquired a new position in shares of Rafael during the second quarter worth $173,000. Finally, Kahn Brothers Group Inc. acquired a new position in shares of Rafael during the second quarter worth $494,000. 11.30% of the stock is currently owned by institutional investors.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.